MedWatch

Zealand Pharma delivers best result ever

Following a European approval of a diabetes drug, the Danish company Zealand Pharma has secured a better financial result than ever before, however, there is still some uncertainty about revenue in 2013.

Foto: Zealand Pharma/PR

2012 was a crucial year for Zealand Pharma, which can be seen in both the top and bottom line of the company’s recently-published full-year results. The biotech company presented turnover of 224 million kroner (EUR 30 million) and net results of 36 million kroner (EUR 5 million) in 2012 – the best financial result in the history of the company.

“2012 was a decisive year for Zealand, culminating in November with the positive CHMP recommendation for approval of Lyxumia in Europe. This was followed in February this year by the formal Marketing Authorization for the drug, recently resulting in first sales of this Zealand discovered medicine to benefit patients,” CEO David Solomon says in a statement.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Permanent forhøjet forskningsfradrag begejstrer – men ikke uden forbehold

Det vækker begejstring hos branche- og erhvervsorganisationer, at et flertal i Folketinget fredag blev enige om en aftale, der blandt andet betyder, at fradraget for forskning og udvikling permanent forhøjes til 130 pct. Fradraget kræver imidlertid, at aftaleparterne kan finde finansieringen engang til efteråret, og uvisheden giver anledning til bekymring.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier